American Academy of Ophthalmology 2022 Annual Meeting

Sep 302022 4:24 PM EDT Sep 30, 2022 | 4:24 PM EDT

These slides contain the 48-week results from the Phase 2/3 PHOTON study (by Dr. David M. Brown) and the Phase 3 PULSAR study (by Dr. Paolo Lanzetta) of aflibercept 8 mg for DME and nAMD, respectively, as presented at AAO 2022 on September 30, 2022.

Supporting Materials